Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PTGIR | P43119 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249813 | 0.93 | ACHE (0.47) | ACHECHRM2CHRM1CHRM3OPRM1 | |
| SCHEMBL4250571 | 0.92 | CHRM2 (0.52) | ACHECHRM2CHRM1CHRM3OPRM1 | |
| SCHEMBL4237271 | 0.92 | CHRM2 (0.46) | ACHECHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL4246952 | 0.90 | CHRM2 (0.48) | ACHECHRM2CHRM1CHRM3OPRM1 | |
| SCHEMBL4237509 | 0.89 | PTGIR (0.50) | ACHEPTGIRPTGER4PTGER3PTGER2 | |
| SCHEMBL4248307 | 0.88 | CHRM2 (0.52) | ACHECHRM2CHRM1CHRM3OPRM1 | |
| SCHEMBL4246887 | 0.87 | CHRM1 (0.49) | ACHECHRM2CHRM1CHRM3OPRM1 | |
| SCHEMBL4240764 | 0.85 | CHRM1 (0.46) | ACHECHRM2CHRM1CHRM3OPRM1 | |
| SCHEMBL4244214 | 0.84 | KCNH2 (0.45) | ACHECHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL4245563 | 0.83 | ACHE (0.49) | ACHECHRM2CHRM1CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | ACHE 108/4885CHRM2 2/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.